Intrinsic value of Endologix - ELGX

Previous Close

$5.51

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$5.51

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of ELGX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  185
  189
  194
  199
  205
  212
  219
  227
  235
  244
  254
  264
  275
  287
  299
  312
  326
  341
  356
  373
  390
  408
  428
  448
  469
  492
  515
  540
  566
  594
Variable operating expenses, $m
  275
  281
  287
  295
  303
  312
  322
  333
  345
  357
  350
  364
  380
  396
  413
  431
  450
  470
  492
  514
  538
  563
  590
  618
  647
  678
  710
  745
  781
  819
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  275
  281
  287
  295
  303
  312
  322
  333
  345
  357
  350
  364
  380
  396
  413
  431
  450
  470
  492
  514
  538
  563
  590
  618
  647
  678
  710
  745
  781
  819
Operating income, $m
  -90
  -92
  -94
  -96
  -98
  -100
  -103
  -106
  -109
  -113
  -96
  -100
  -104
  -109
  -113
  -118
  -124
  -129
  -135
  -141
  -148
  -155
  -162
  -170
  -178
  -186
  -195
  -205
  -215
  -225
EBITDA, $m
  -47
  -48
  -49
  -51
  -52
  -54
  -56
  -58
  -60
  -62
  -65
  -67
  -70
  -73
  -76
  -80
  -83
  -87
  -91
  -95
  -100
  -104
  -109
  -114
  -120
  -125
  -131
  -138
  -144
  -151
Interest expense (income), $m
  6
  25
  25
  26
  27
  28
  29
  30
  31
  33
  34
  36
  38
  39
  41
  43
  46
  48
  50
  53
  56
  59
  62
  65
  68
  72
  76
  79
  84
  88
  93
Earnings before tax, $m
  -115
  -117
  -120
  -123
  -126
  -129
  -133
  -138
  -142
  -147
  -132
  -138
  -144
  -150
  -157
  -164
  -172
  -180
  -188
  -197
  -206
  -216
  -227
  -238
  -250
  -262
  -275
  -288
  -303
  -318
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -115
  -117
  -120
  -123
  -126
  -129
  -133
  -138
  -142
  -147
  -132
  -138
  -144
  -150
  -157
  -164
  -172
  -180
  -188
  -197
  -206
  -216
  -227
  -238
  -250
  -262
  -275
  -288
  -303
  -318

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  372
  381
  391
  402
  414
  427
  442
  457
  474
  493
  512
  533
  555
  578
  603
  630
  658
  687
  719
  752
  787
  823
  862
  903
  946
  991
  1,039
  1,089
  1,142
  1,197
Adjusted assets (=assets-cash), $m
  372
  381
  391
  402
  414
  427
  442
  457
  474
  493
  512
  533
  555
  578
  603
  630
  658
  687
  719
  752
  787
  823
  862
  903
  946
  991
  1,039
  1,089
  1,142
  1,197
Revenue / Adjusted assets
  0.497
  0.496
  0.496
  0.495
  0.495
  0.496
  0.495
  0.497
  0.496
  0.495
  0.496
  0.495
  0.495
  0.497
  0.496
  0.495
  0.495
  0.496
  0.495
  0.496
  0.496
  0.496
  0.497
  0.496
  0.496
  0.496
  0.496
  0.496
  0.496
  0.496
Average production assets, $m
  229
  234
  240
  247
  254
  262
  271
  281
  291
  303
  315
  327
  341
  355
  371
  387
  404
  422
  442
  462
  483
  506
  530
  555
  581
  609
  638
  669
  702
  736
Working capital, $m
  33
  34
  35
  36
  37
  38
  40
  41
  43
  44
  46
  48
  50
  52
  54
  57
  59
  62
  65
  67
  71
  74
  77
  81
  85
  89
  93
  98
  102
  107
Total debt, $m
  231
  238
  246
  254
  264
  275
  286
  299
  312
  327
  342
  358
  376
  395
  415
  436
  458
  481
  506
  532
  560
  589
  620
  652
  686
  722
  760
  800
  842
  886
Total liabilities, $m
  296
  302
  310
  319
  328
  339
  351
  363
  377
  391
  407
  423
  441
  459
  479
  500
  522
  546
  571
  597
  625
  654
  684
  717
  751
  787
  825
  865
  906
  950
Total equity, $m
  77
  78
  80
  83
  85
  88
  91
  94
  98
  101
  105
  110
  114
  119
  124
  130
  136
  142
  148
  155
  162
  170
  178
  186
  195
  204
  214
  224
  235
  247
Total liabilities and equity, $m
  373
  380
  390
  402
  413
  427
  442
  457
  475
  492
  512
  533
  555
  578
  603
  630
  658
  688
  719
  752
  787
  824
  862
  903
  946
  991
  1,039
  1,089
  1,141
  1,197
Debt-to-equity ratio
  3.010
  3.030
  3.050
  3.070
  3.100
  3.120
  3.140
  3.170
  3.190
  3.220
  3.240
  3.270
  3.290
  3.310
  3.330
  3.360
  3.380
  3.400
  3.420
  3.440
  3.460
  3.470
  3.490
  3.510
  3.520
  3.540
  3.550
  3.570
  3.580
  3.590
Adjusted equity ratio
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206
  0.206

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -115
  -117
  -120
  -123
  -126
  -129
  -133
  -138
  -142
  -147
  -132
  -138
  -144
  -150
  -157
  -164
  -172
  -180
  -188
  -197
  -206
  -216
  -227
  -238
  -250
  -262
  -275
  -288
  -303
  -318
Depreciation, amort., depletion, $m
  43
  44
  44
  45
  46
  46
  47
  48
  49
  50
  31
  33
  34
  36
  37
  39
  40
  42
  44
  46
  48
  51
  53
  55
  58
  61
  64
  67
  70
  74
Funds from operations, $m
  -72
  -74
  -76
  -78
  -80
  -83
  -86
  -89
  -93
  -97
  -101
  -105
  -110
  -115
  -120
  -125
  -131
  -137
  -144
  -151
  -158
  -166
  -174
  -182
  -191
  -201
  -211
  -221
  -232
  -244
Change in working capital, $m
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
Cash from operations, $m
  -73
  -74
  -76
  -79
  -81
  -84
  -87
  -91
  -94
  -98
  -102
  -107
  -112
  -117
  -122
  -128
  -134
  -140
  -147
  -154
  -161
  -169
  -177
  -186
  -195
  -205
  -215
  -226
  -237
  -249
Maintenance CAPEX, $m
  -22
  -23
  -23
  -24
  -25
  -25
  -26
  -27
  -28
  -29
  -30
  -31
  -33
  -34
  -36
  -37
  -39
  -40
  -42
  -44
  -46
  -48
  -51
  -53
  -55
  -58
  -61
  -64
  -67
  -70
New CAPEX, $m
  -4
  -5
  -6
  -7
  -7
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -14
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -23
  -24
  -25
  -26
  -28
  -29
  -31
  -32
  -34
Cash from investing activities, $m
  -26
  -28
  -29
  -31
  -32
  -33
  -35
  -37
  -38
  -40
  -42
  -44
  -47
  -48
  -51
  -53
  -56
  -58
  -61
  -64
  -67
  -71
  -75
  -78
  -81
  -86
  -90
  -95
  -99
  -104
Free cash flow, $m
  -99
  -102
  -106
  -110
  -114
  -118
  -123
  -128
  -133
  -139
  -145
  -151
  -158
  -165
  -173
  -181
  -190
  -199
  -208
  -218
  -229
  -240
  -252
  -264
  -277
  -291
  -305
  -320
  -336
  -353
Issuance/(repayment) of debt, $m
  5
  7
  8
  9
  10
  11
  12
  13
  13
  14
  15
  16
  18
  19
  20
  21
  22
  24
  25
  26
  28
  29
  31
  32
  34
  36
  38
  40
  42
  44
Issuance/(repurchase) of shares, $m
  117
  119
  122
  125
  128
  132
  136
  141
  146
  151
  136
  142
  148
  155
  162
  169
  177
  186
  194
  204
  214
  224
  235
  246
  258
  271
  285
  299
  313
  329
Cash from financing (excl. dividends), $m  
  122
  126
  130
  134
  138
  143
  148
  154
  159
  165
  151
  158
  166
  174
  182
  190
  199
  210
  219
  230
  242
  253
  266
  278
  292
  307
  323
  339
  355
  373
Total cash flow (excl. dividends), $m
  23
  23
  24
  24
  24
  25
  25
  26
  26
  27
  7
  7
  8
  8
  9
  9
  10
  11
  11
  12
  12
  13
  14
  15
  15
  16
  17
  18
  19
  20
Retained Cash Flow (-), $m
  -117
  -119
  -122
  -125
  -128
  -132
  -136
  -141
  -146
  -151
  -136
  -142
  -148
  -155
  -162
  -169
  -177
  -186
  -194
  -204
  -214
  -224
  -235
  -246
  -258
  -271
  -285
  -299
  -313
  -329
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  12
  12
  12
  12
  13
  13
  14
  14
  15
  15
  16
  16
  17
  18
  18
  19
  20
  21
  22
  23
  24
  25
  26
  27
  29
  30
  31
  33
  35
  36
Cash available for distribution, $m
  -94
  -96
  -98
  -101
  -104
  -107
  -111
  -115
  -119
  -124
  -129
  -135
  -140
  -147
  -153
  -160
  -167
  -175
  -183
  -192
  -201
  -211
  -221
  -232
  -243
  -255
  -267
  -281
  -295
  -309
Discount rate, %
  10.00
  10.50
  11.03
  11.58
  12.16
  12.76
  13.40
  14.07
  14.77
  15.51
  16.29
  17.10
  17.96
  18.86
  19.80
  20.79
  21.83
  22.92
  24.07
  25.27
  26.53
  27.86
  29.25
  30.72
  32.25
  33.86
  35.56
  37.33
  39.20
  41.16
PV of cash for distribution, $m
  -85
  -78
  -72
  -65
  -59
  -52
  -46
  -40
  -35
  -29
  -25
  -20
  -16
  -13
  -10
  -8
  -6
  -4
  -3
  -2
  -1
  -1
  -1
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  79.7
  63.5
  50.7
  40.4
  32.2
  25.7
  20.5
  16.3
  13.0
  10.4
  8.5
  7.0
  5.7
  4.7
  3.8
  3.1
  2.6
  2.1
  1.7
  1.4
  1.1
  0.9
  0.8
  0.6
  0.5
  0.4
  0.3
  0.3
  0.2
  0.2

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

FINANCIAL RATIOS  of  Endologix (ELGX)

Valuation Ratios
P/E Ratio -2.9
Price to Sales 2.4
Price to Book 4
Price to Tangible Book
Price to Cash Flow -6.1
Price to Free Cash Flow -5.8
Growth Rates
Sales Growth Rate 25.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -25%
Cap. Spend. - 3 Yr. Gr. Rate 0%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 156.6%
Total Debt to Equity 156.6%
Interest Coverage -25
Management Effectiveness
Return On Assets -43.1%
Ret/ On Assets - 3 Yr. Avg. -23.9%
Return On Total Capital -55.3%
Ret/ On T. Cap. - 3 Yr. Avg. -31.4%
Return On Equity -143.5%
Return On Equity - 3 Yr. Avg. -71.8%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 64.2%
Gross Margin - 3 Yr. Avg. 67.4%
EBITDA Margin -72%
EBITDA Margin - 3 Yr. Avg. -41.3%
Operating Margin -48.2%
Oper. Margin - 3 Yr. Avg. -32.3%
Pre-Tax Margin -79.8%
Pre-Tax Margin - 3 Yr. Avg. -46.8%
Net Profit Margin -80.3%
Net Profit Margin - 3 Yr. Avg. -44.8%
Effective Tax Rate -0.6%
Eff/ Tax Rate - 3 Yr. Avg. 5.3%
Payout Ratio 0%

ELGX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ELGX stock intrinsic value calculation we used $181 million for the last fiscal year's total revenue generated by Endologix. The default revenue input number comes from 2017 income statement of Endologix. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ELGX stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 10%, whose default value for ELGX is calculated based on our internal credit rating of Endologix, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Endologix.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ELGX stock the variable cost ratio is equal to 149%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ELGX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 11% for Endologix.

Corporate tax rate of 27% is the nominal tax rate for Endologix. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ELGX stock is equal to 6.4%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ELGX are equal to 123.9%.

Life of production assets of 10 years is the average useful life of capital assets used in Endologix operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ELGX is equal to 18.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $75 million for Endologix - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 83 million for Endologix is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Endologix at the current share price and the inputted number of shares is $0.5 billion.

RELATED COMPANIES Price Int.Val. Rating
CSII Cardiovascular 34.80 0.88  str.sell
LMAT LeMaitre Vascu 36.36 22.87  sell
ANGO AngioDynamics 20.83 6.70  str.sell
TCMD Tactile System 54.26 3.71  str.sell
BSX Boston Scienti 33.15 6.87  str.sell

COMPANY NEWS

▶ Endologix Appoints Jeffry Fecho as Chief Quality Officer   [Jun-25-18 04:01PM  Business Wire]
▶ What Is Endologix Incs (NASDAQ:ELGX) Share Price Doing?   [Jun-07-18 11:06AM  Simply Wall St.]
▶ Endologix: 1Q Earnings Snapshot   [May-02-18 07:17PM  Associated Press]
▶ Endologix reports 4Q loss   [Feb-21-18 05:09PM  Associated Press]
▶ Endologix, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ Endologix Q4 Earnings Preview   [10:50AM  Benzinga]
▶ At $4.27, Is It Time To Buy Endologix Inc (NASDAQ:ELGX)?   [Jan-19-18 12:25PM  Simply Wall St.]
▶ ETFs with exposure to Endologix, Inc. : December 7, 2017   [Dec-07-17 01:38PM  Capital Cube]
▶ Endologix reports 3Q loss   [Nov-07-17 04:51PM  Associated Press]
▶ Endologix, Inc. to Host Earnings Call   [10:10AM  ACCESSWIRE]
▶ Is Endologix Inc (ELGX) A Financially Sound Company?   [Oct-30-17 04:51PM  Simply Wall St.]
▶ ETFs with exposure to Endologix, Inc. : October 27, 2017   [Oct-27-17 10:52AM  Capital Cube]
▶ What Does Endologix Incs (ELGX) Share Price Indicate?   [Oct-16-17 03:37PM  Simply Wall St.]
▶ ETFs with exposure to Endologix, Inc. : October 3, 2017   [Oct-03-17 11:11AM  Capital Cube]
▶ What Are The Drivers Of Endologix Incs (ELGX) Risks?   [Sep-30-17 04:02PM  Simply Wall St.]
▶ Is There Now An Opportunity In Endologix Inc (ELGX)?   [Sep-13-17 08:31PM  Simply Wall St.]
▶ Endologix reports 2Q loss   [Aug-02-17 10:59PM  Associated Press]
▶ ETFs with exposure to Endologix, Inc. : May 26, 2017   [May-26-17 01:06PM  Capital Cube]
▶ Why Endologix Shares Are Hitting a Multiyear Low   [May-18-17 12:30PM  24/7 Wall St.]
▶ ETFs with exposure to Endologix, Inc. : May 11, 2017   [May-11-17 04:35PM  Capital Cube]
▶ Endologix reports 1Q loss   [May-04-17 05:14PM  Associated Press]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.